Literature DB >> 3682431

Natural killer activity of peripheral blood lymphocytes and its relation to histopathological factors of lung cancer.

A Terazawa1, N Tanaka, N Senou, F Inoue, H Matsuura, A Gouchi, S Fuchimoto, H Mimura, K Orita.   

Abstract

This investigation was intended to determine whether the natural killer (NK) activity of peripheral blood lymphocytes (PBL) correlated with the histopathological factor, which is thought to be a result of a balance between tumor aggression and host resistance. The NK activity of PBL from 60 patients with lung cancer was measured by the lysis of 51Cr-labelled K562 target cells. The activity was significantly decreased with advancing stages of the disease, and inversely correlated with increased immunosuppressive substance levels of the serum. Histopathological factors, such as low grade pleural invasion of the tumor and abundant lymphoid cell infiltration around the tumor, were significantly associated with the high NK activity of PBL. These results show that a decrease in NK activity may play a role in identifying those individuals with a greater risk of cancer development.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3682431     DOI: 10.1007/bf02470694

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  22 in total

1.  Cellular responses to autologous breast cancer tissue. Correlation with stage and lymphoreticuloendothelial reactive.

Authors:  M M Black; H P Leis
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

2.  Delayed cutaneous hypersensitivity reactions to tumor cell antigens and to nonspecific antigens. Prognostic significance in patients with lung cancer.

Authors:  S A Wells; J F Burdick; W L Joseph; C L Christiansen; W G Wolfe; P C Adkins
Journal:  J Thorac Cardiovasc Surg       Date:  1973-10       Impact factor: 5.209

3.  Immunologic alterations in bronchogenic cancer. Sequential study.

Authors:  M J Krant; G Manskopf; C S Brandrup; M A Madoff
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

4.  Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer.

Authors:  D R Strayer; W A Carter; S D Mayberry; E Pequignot; I Brodsky
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

5.  Spontaneous human lymphocyte-mediated cytotoxicity againts tumour target cells. I. The effect of malignant disease.

Authors:  H F Pross; M G Baines
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

6.  Human tumour--lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells.

Authors:  B M Vose; F Vánky; E Klein
Journal:  Int J Cancer       Date:  1977-12-15       Impact factor: 7.396

7.  Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients.

Authors:  K Tamura; Y Shibata; Y Matsuda; N Ishida
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

8.  Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years.

Authors:  H J Bloom; W W Richardson; J R Field
Journal:  Br Med J       Date:  1970-07-25

9.  Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism.

Authors:  M H Greene; R N Hoover; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1978-08       Impact factor: 13.506

10.  Immune reactivity in primary carcinoma of the lung and its relation to prognosis.

Authors:  H J Wanebo; B Rao; N Miyazawa; N Martini; M P Middleman; H F Oettgen; E J Beattie
Journal:  J Thorac Cardiovasc Surg       Date:  1976-09       Impact factor: 5.209

View more
  1 in total

1.  Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels.

Authors:  A D Cohen; Y Shoenfeld; J Gopas; Y Cohen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.